Chronic eosinophilic leukemia, not otherwise specified
Clinical trials for Chronic eosinophilic leukemia, not otherwise specified explained in plain language.
Never miss a new study
Get alerted when new Chronic eosinophilic leukemia, not otherwise specified trials appear
Sign up with your email to follow new studies for Chronic eosinophilic leukemia, not otherwise specified, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare blood disorder: drug targets overactive immune cells
Disease control OngoingThis phase 2 trial is testing the drug ruxolitinib in people with hypereosinophilic syndrome, a rare condition where the body produces too many eosinophils (a type of white blood cell), causing organ damage. The study aims to see if ruxolitinib can normalize blood cell counts and…
Matched conditions: CHRONIC EOSINOPHILIC LEUKEMIA, NOT OTHERWISE SPECIFIED
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 part…
Matched conditions: CHRONIC EOSINOPHILIC LEUKEMIA, NOT OTHERWISE SPECIFIED
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC